Trial Profile
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 16 Jun 2023 Results published in the Clinical Cancer Research
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology